Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Oruka Therapeutics, retaining the price target of $41.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors, primarily focusing on Oruka Therapeutics’ potential to significantly impact the global psoriasis market, which is valued at over $30 billion. The company’s innovative treatments, ORKA-001 and ORKA-002, target key cytokines involved in psoriasis, offering a novel approach that could differentiate them from existing therapies.
Oruka’s ORKA-001 is currently being evaluated in a Phase 1 trial, with a Phase 2a study planned for 2026. This study aims to explore ORKA-001’s potential advantages over current IL-23 inhibitors, such as more convenient dosing schedules, improved rates of deep responders, and the possibility of inducing long-term treatment-free remissions. Depending on the outcomes, Oruka has strategic options for commercialization, either through pharmacy-benefit or medical-benefit reimbursement paths, which could enhance market access and adoption.